Salix Pharmaceuticals Ltd

Salix Pharmaceuticals — Proxy Contest (June 2003)

37 slides from Salix Pharmaceuticals's proxy contest presentation, Jun 13, 2003

  1. Slide 1: Presentation to Institutional Shareholder Services

    Exhibit 99.2 Salix Pharmaceuticals, Ltd. Presentation to Institutional Shareholder Services June 4, 2003 Salix Pharmaceuticals, Ltd.

  2. Slide 2: Why Support the Incumbent Board of Directors?

    WHY SUPPORT THE INCUMBENT BOARD OF DIRECTORS? Strong business execution — Salix’s Board has consistently made decisions that have enhanced stockholder value — Salix is at the cusp of realizing the benefit of our efforts and success in executing our business plan — Salix is poised for significant gro

  3. Slide 3: Corporate Profile

    CORPORATE PROFILE Specialty pharmaceutical company n Gastroenterology-focused Headquarters: Raleigh, NC 135 employees n 84-member sales and marketing team COLAZAL ® product revenues — 2001 $14.1 million — 2002 $33.5 million — 2003 $53E million — 2004 $70—73E million

  4. Slide 4: Mission Statement

    MISSION STATEMENT Salix Pharmaceuticals is dedicated to being the leading specialty pharmaceutical company providing products to gastroenterologists and their patients

  5. Slide 5: Salix Has a Clear, Focused Strategy

    SALIX HAS A CLEAR, FOCUSED STRATEGY Enhance stockholder value: In-license selective late-stage/marketed product candidates — U.S. gastroenterology focus — Reduce risk and capital commitment Complete any required development and secure FDA approval Sell products through specialty sales force — Establ

  6. Slide 6: Salix Has Successfully Executed Its Business Plan

    SALIX HAS SUCCESSFULLY EXECUTED ITS BUSINESS PLAN Premier Specialty Sales Force COLAZAL ® —approved and marketed Rifaximin—FDA approvable letter Granulated mesalamine—scheduled to enter Phase III

  7. Slide 7: Premier Gastroenterology Sales Force

    PREMIER GASTROENTEROLOGY SALES FORCE 84-member sales and marketing team Experienced, incentivized professionals Reputation for integrity and quality Established franchise with gastroenterologists Infrastructure in place to be leveraged with future products

  8. Slide 8: COLAZAL

    COLAZAL Approved for first-line treatment of mildly to moderately active ulcerative colitis (UC) The fastest growing drug of its kind in the marketplace based upon 2002 prescriptions COLAZAL revenue alone is expected to provide profitability in the second half of 2004

  9. Slide 9: COLAZAL Total Prescriptions

    COLAZAL TOTAL PRESCRIPTIONS [GRAPHICS APPEARS HERE] Source: NDC

  10. Slide 10: 5-ASA Market Share Change Since COLAZAL Launch

    5-ASA MARKET SHARE CHANGE SINCE COLAZAL LAUNCH [GRAPHICS APPEARS HERE] Source: NDC Health Called-On Physicians

  11. Slide 11: Rifaximin

    RIFAXIMIN A unique, broad-spectrum, gastrointestinal-specific, non-absorbed, oral antibiotic FDA approvable letter received October 2002 FDA approvable letter response—4Q/2003 Anticipated launch—mid-2004 Approval in 2004 provides profitability for 2004 Expected to be bigger than COLAZAL with a poten

  12. Slide 12: Rifaximin (Continued)

    RIFAXIMIN (CONTINUED) Travelers’ diarrhea—First indication Over 100 clinical publications for a broad range of GI diseases Clinical studies for additional potential uses — Completed n Hepatic encephalopathy, Crohn’s disease — Ongoing n Pouchitis, C. difficile- associated diarrhea — Soon-to-be-initia

  13. Slide 13: Granulated Mesalamine

    GRANULATED MESALAMINE In-licensed from Dr. Falk Pharma, a leading European gastroenterology company Given unique release mechanism, Salix intends to develop for: — expanded ulcerative colitis treatment options — improved dosing regimens Patent protected to 2018 First right of negotiation for certain

  14. Slide 14: Salix Is Successfully Executing Its Business Plan

    SALIX IS SUCCESSFULLY EXECUTING ITS BUSINESS PLAN Salix has made tremendous progress over three years in building a thriving specialty pharmaceutical franchise Salix has proven its ability to in-license, complete any required development, and launch and sell drugs through our focused specialty sales

  15. Slide 15: Corporate Governance

    CORPORATE GOVERNANCE

  16. Slide 16: Salix Is Governed by an Independent Board

    SALIX IS GOVERNED BY AN INDEPENDENT BOARD John F. Chappell IO Former Chairman, Worldwide Pharmaceuticals, SmithKline Beecham plc (28 yrs pharmaceutical executive) Thomas W. D’Alonzo IO Former President, PPD, Inc. & Glaxo, Inc. (17 yrs pharmaceutical executive) Richard A. Franco IO Former Chairman an

  17. Slide 17: Key Board Committees Are Fully Independent

    KEY BOARD COMMITTEES ARE FULLY INDEPENDENT Audit, Compensation and Nominating Committee members John F. Chappell Chair, Compensation Thomas W. D’Alonzo Chair, Audit Richard A. Franco Chair, Nominating

  18. Slide 18: Salix Board's Interests Are Aligned with Its Stockholders

    SALIX BOARD’S INTERESTS ARE ALIGNED WITH ITS STOCKHOLDERS Shares Owned % O.S.** Salix Directors* 1,624,396 7.6 % Axcan (Saule Holdings) 0.0005 % * Salix Officers and Directors hold an aggregate of 3.3 million shares of SLXP common stock, representing 15.5 % of O.S. The aggregate market value of thei

  19. Slide 19: Salix Practices Good Corporate Governance

    SALIX PRACTICES GOOD CORPORATE GOVERNANCE All directors elected annually Stockholders can amend the bylaws by majority vote Holders of 10% can call special meetings Merger can be approved by simple majority vote Original Rights Plan approved by stockholders

  20. Slide 20: Salix Practices Good Corporate Governance (Continued)

    SALIX PRACTICES GOOD CORPORATE GOVERNANCE (CONTINUED) The CEO and Chairman roles are separated, and have been since 1999 All directors have excellent meeting attendance Non-audit fees consistently lower than audit fees Auditor appointment ratified by stockholders annually Active involvement of outsi

  21. Slide 21: Shareholder Rights Plan

    SHAREHOLDER RIGHTS PLAN Approved by shareholders (94% of votes cast) in June 2000 Updated January 2003 after Salix: — Reincorporated from a British Virgin Islands corporation to a Delaware corporation in 2002 — Changed from Toronto Stock Exchange listing to Nasdaq listing in 2000 Plan was not update

  22. Slide 22: Good Corporate Governance in Action

    GOOD CORPORATE GOVERNANCE IN ACTION The Salix Board has a record of carefully considering indications of interest and being advised of, understanding and complying with, their fiduciary duties AXCAN Tender Offer Board has met formally 6 times — over 17 hours of meetings/deliberations Sought and util

  23. Slide 23: Salix Has Always Been Willing to Meet with Third Parties

    SALIX HAS ALWAYS BEEN WILLING TO MEET WITH THIRD PARTIES AND DISCUSS STRATEGIC ALTERNATIVES CONTACTS WITH AXCAN April 1999—January 2003 During this period, Salix estimates that there were over 30 communications between Salix and Axcan in the form of meetings, telephone calls, letters and substantive

  24. Slide 24: Salix Has Always Been Willing to Meet (Continued)

    SALIX HAS ALWAYS BEEN WILLING TO MEET WITH THIRD PARTIES AND DISCUSS STRATEGIC ALTERNATIVES (CONTINUED) CONTACTS WITH AXCAN January 2003—April 2003 January 2003 Salix seeks to postpone meeting scheduled for January 30, 2003 February—March 2003 No communication between Salix and Axcan April 2003 Axca

  25. Slide 25: Board History of Strategic Decisions That Enhance Stockholder Value

    THE SALIX BOARD HAS A HISTORY OF MAKING STRATEGIC DECISIONS THAT ENHANCE STOCKHOLDER VALUE Axcan first sought to acquire Salix on Dec. 14, 1999 when SLXP stock was trading on the TSE at US$ 0.12 per share — The Salix Board determined that its stock at that time did not adequately reflect true value

  26. Slide 26: Salix Has Added Significant Stockholder Value

    SALIX HAS ADDED SIGNIFICANT STOCKHOLDER VALUE SLXP and AXCA Relative Stock Price Performance Between Axcan’s 12/14/99 Initial Inquiry and one day prior to its 4/10/03 Offer SLXP: 62-fold increase AXCA: 2.7-fold increase Clearly, by successfully implementing its current business plan initiated in 199

  27. Slide 27: Stockholders Will Once Again Be Better Served by Executing the Business Plan

    THE SALIX BOARD BELIEVES STOCKHOLDERS WILL ONCE AGAIN BE BETTER SERVED BY EXECUTING THE BUSINESS PLAN Now, 12 months prior to the projected launch of Salix’s second product, Rifaximin, Axcan is once again trying to acquire Salix at a time when Salix is poised for substantial growth, but when its sto

  28. Slide 28: Valuation Considerations

    VALUATION CONSIDERATIONS

  29. Slide 29: Peer Group Valuation Shows Salix Is Significantly Undervalued

    PEER GROUP VALUATION SHOWS SALIX IS SIGNIFICANTLY UNDERVALUED ENTERPRISE VALUE* / REVENUE Valuation Data Comparable Company(1) 6/2/2003 Price Revenue(2) Enterprise Value/ Revenue(3) LTM 2003E 2004E LTM 2003E 2004E Alkermes $ 13.11 $ 15.5 $ 52.0 $ 67.2 18.9x 17.3x 13.4x Connetics 16.53 51.7 69.2 93.1

  30. Slide 30: Independent Research: Analysts' Comments

    INDEPENDENT RESEARCH ANALYSTS’ COMMENTS The following five (5) slides show selected comments from research analysts that cover Salix Pharmaceuticals, Ltd. Salix has retained the investment banking division of Wachovia Securities as its financial advisor in connection with the Axcan hostile tender of

  31. Slide 31: Analysts' Comments: Axcan Tender Offer and Salix Strategic Plan

    INDEPENDENT RESEARCH ANALYSTS’ COMMENTS AXCAN TENDER OFFER AND SALIX STRATEGIC PLAN “Axcan has raised its hostile offer for SLXP to $10.50 per share (from $8.75 per share)…We believe that the new bid does not fully reflect the potential of rifaximin…We believe SLXP shareholders could potentially der

  32. Slide 32: Analysts' Comments: Tender Offer and Strategic Plan (Continued)

    INDEPENDENT RESEARCH ANALYSTS’ COMMENTS (CONTINUED) AXCAN TENDER OFFER AND SALIX STRATEGIC PLAN “We believe SLXP’s current share price does not fully reflect Rifaximin’s intrinsic value potential.” (M Tong—Wachovia 5/14/03) “We believe the Company has sufficient financial flexibility to execute prod

  33. Slide 33: Analysts' Comments: COLAZAL

    INDEPENDENT RESEARCH ANALYSTS’ COMMENTS (CONTINUED) COLAZAL “The company has raised its forecast for 2003 COLAZAL sales to $53 million from $50 million…Note that as of the week ending 5/2/03, COLAZAL had an annual run rate of almost $58 million…, which could indicate that the company’s expectations

  34. Slide 34: Analysts' Comments: Rifaximin

    INDEPENDENT RESEARCH ANALYSTS’ COMMENTS (CONTINUED) RIFAXIMIN “We continue to believe that the company will provide the FDA with all necessary data for a Rifaximin approval in mid-2004 and that this will drive company profitability.. We believe this (travelers’ diarrhea) represents the first of seve

  35. Slide 35: Analysts' Comments: Granulated Mesalamine

    INDEPENDENT RESEARCH ANALYSTS’ COMMENTS (CONTINUED) GRANULATED MESALAMINE “Given the potential for improved dosing (qd or bid vs. current tid administration), we believe peak sales (of granulated mesalamine product) could be $250-300MM—addressing a market of roughly 500,000 adults in the U.S.” (M He

  36. Slide 36: Why Support the Incumbent Board of Directors?

    WHY SUPPORT THE INCUMBENT BOARD OF DIRECTORS? Strong business execution — Salix’s Board has consistently made decisions that have enhanced stockholder value — Salix is at the cusp of realizing the benefit of our efforts and success in executing our business plan — Salix is poised for significant gro

  37. Slide 37: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS Statements presented in this overview which are not historical facts are forward looking statements that involve risks and uncertainties that could cause actual results to differ from projected results. Factors that could cause actual results to differ materially include o

Salix Pharmaceuticals — Proxy Contest (June 2003) on 6ix